Revolution Medicines, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
RVMD$200.15+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $615,908 | $383,745 |
| Marketable securities | 3,035,477 | 1,641,934 |
| Accounts receivable, net | 230,724 | — |
| Inventory | 11,018 | — |
| Prepaid expenses and other current assets | 83,571 | 49,358 |
| Total current assets | 3,976,698 | 2,075,037 |
| Property and equipment, net | 34,628 | 33,194 |
| Operating lease right-of-use asset | 125,395 | 132,084 |
| Intangible assets, net | 55,474 | 55,800 |
| Goodwill | 14,608 | 14,608 |
| Restricted cash | 15,830 | 4,858 |
| Long-term deposits | 65,651 | 24,148 |
| Other noncurrent assets | 15,230 | 14,779 |
| Total assets | $4,303,514 | $2,354,508 |
| Liabilities and stockholdersʼ equity | ||
| Current liabilities: | ||
| Accounts payable | $100,656 | $64,616 |
| Accrued expenses and other current liabilities | 365,630 | 209,340 |
| Operating lease liability, current | 9,381 | 16,468 |
| Total current liabilities | 475,667 | 290,424 |
| Deferred tax liability | — | 2,353 |
| Operating lease liability, noncurrent | 141,842 | 142,234 |
| Liability related to the sale of future royalties | 572,311 | 268,446 |
| Convertible senior notes, noncurrent | 487,880 | — |
| Warrant liability | 224,311 | 18,546 |
| Other noncurrent liabilities | — | 1,208 |
| Total liabilities | 1,902,011 | 723,211 |
| Commitments and contingencies (Note 8) | ||
| Stockholdersʼ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; none issued and outstanding at September 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 216,251,663 and 197,001,401 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 22 | 19 |
| Additional paid-in capital | 6,790,896 | 4,497,143 |
| Accumulated other comprehensive income (loss) | (14,669) | 3,237 |
| Accumulated deficit | (4,374,746) | (2,869,102) |
| Total stockholdersʼ equity | 2,401,503 | 1,631,297 |
| Total liabilities and stockholdersʼ equity | $4,303,514 | $2,354,508 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.